Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (32)

2024

  1. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

  2. Longitudinal Study of Different Progression Patterns in High-Risk Cutaneous Squamous Cell Carcinoma

    Actas Dermo-Sifiliograficas

  3. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology

2023

  1. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  2. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

    Cell Reports Medicine, Vol. 4, Núm. 12

  3. Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study

    Journal of the American Academy of Dermatology, Vol. 89, Núm. 1, pp. 119-127

  4. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study

    Dermatology (Basel, Switzerland), Vol. 239, Núm. 5, pp. 685-693

  5. Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605

  6. [Translated article] Tumor Doubling Time in Skin Cancer: Can It Be Estimated and Is It Useful?

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 3, pp. T247-T252

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Effects of covid-19 lockdown on tumour burden of melanoma and cutaneous squamous cell carcinoma

    Acta Dermato-Venereologica, Vol. 101, Núm. 8

  2. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  3. Sentinel lymph node biopsy vs. Observation in thin melanoma: A multicenter propensity score matching study

    Journal of Clinical Medicine, Vol. 10, Núm. 24

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. A review of terms used to define cutaneous squamous cell carcinoma with a poor prognosis

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 4, pp. 281-290

  3. Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 8, pp. 629-638

  4. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  5. Predictive Value of Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Based on the AJCC-8 and Brigham and Women's Hospital Staging Criteria

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], Vol. 46, Núm. 7, pp. 857-862

2019

  1. Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)”

    Clinical and Translational Oncology

  2. SEOM clinical guidelines on cardiovascular toxicity (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 94-105